738 J ournal of Natural Products, 1999, Vol. 62, No. 5
Chang et al.
(Lour.) O. Kuntze for this study were re-collected in J anuary
1995, from the suburban mountain of Wen-Xi, Taipei, Taiwan.
A voucher specimen has been deposited in the School of
Pharmacy, National Taiwan University.
Extr a ction a n d Isola tion . The ground, dry powders of the
rhizomes (1.1 kg) were percolated with 95% EtOH (7 L × 5).
The EtOH extract (110 g) was partitioned between H2O (1 L)
and CHCl3 (1 L × 3) to give a CHCl3-soluble fraction (8.10 g).
The aqueous layer, after removal of the residual CHCl3 in
vacuo, was passed through an Amberlite XAD-2 column (2 kg),
washed with H2O, and eluted with 30% to 100% MeOH in H2O,
to give fractions of 30% MeOH (35.01 g), 50% MeOH (3.60 g),
and MeOH (0.98 g).
Part of the 30% MeOH fraction (4.96 g) was further
separated on a Lobar RP8 column (B type, Merck), eluted with
MeOH-H2O (3:7) to give six fractions. Fraction 4 (1.31 g) was
pure nyasicoside (1).2,5,6 Fraction 2 (360 mg out of 952 mg),
containing the mixture of curculigine (4) and isocurculigine
(5),3 was dissolved in MeOH and was O-methylated by reacting
with freshly prepared ethereal CH2N2 at 4 °C for 3 days. The
residue (394 mg) obtained after evaporating the organic
solvents was separated on a Lobar RP8 column (B type, 50%
MeOH in H2O) and subsequently on a preparative C18 HPLC
column (32% MeOH in H2O) to give curculigine tetra-O-methyl
ether (4a , 30 mg) and isocurculigine tetra-O-methyl ether (5a ,
20 mg).
(1S)-Tetr a m eth yl-1-O-m eth yln ya sicosid e (3a ): amor-
phous powder; Rf
0.33 [MeOH-CHCl3 (1:9)]; [R]23 -74.3° (c
D
0.7, MeOH); UV λmax (log ꢀ) 223 (sh, 4.44), 257 (4.36), 285 (3.89),
298 (sh, 3.72) nm; IR νmax 3400 (br s), 2940, 1510, 1460, 1410,
1260, 1240, 1140, 1080, 1020, 900, 860, 820, 760, 620 cm-1
;
CD (1.82 × 10-5 M) (∆ꢀ) 315 (0), 283 (-2.06), 252 (-6.62), 234
(-1.10), 224 (-6.18), 211 (-15.96) nm; 1H NMR (CDCl3) δ 6.96
(1H, dd, J ) 1.7, 8.4 Hz, H-6′′), 6.90 (1H, d, J ) 1.4 Hz, H-2′),
6.88 (1H, d, J ) 1.7 Hz, H-2′′), 6.87 (1H, dd, J ) 1.4, 8.6 Hz,
H-6′), 6.82 (1H, d, J ) 8.6 Hz, H-5′), 6.74 (1H, d, J ) 8.4 Hz,
H-5′′), 4.52 (1H, d, J ) 7.7 Hz, Glc H-1), 4.38 (1H, d, J ) 4.2
Hz, H-1), 4.05 (1H, m, H-2), 3.85 (3H, s, Ar-OMe), 3.83 (9H,
s, Ar-OMe × 3), 3.80 (1H, m) and 3.70 (1H, m) (Glc H-6), 3.28
(3H, s, 1-OMe), 2.74 (1H, dd, J ) 7.6, 17.0 Hz) and 2.53 (1H,
dd, J ) 5.3, 17.0 Hz) (H-3); 13C NMR (CDCl3) δ 149.30 (s, C-4′′),
148.90 (s, C-4′ and C-3′′), 148.62 (s, C-3′), 129.68 (s, C-1′),
124.69 (d, C-6′′), 120.41 (d, C-6′), 114.40 (d, C-2′), 114.31 (s,
C-1′′), 111.05 (d, C-5′′), 110.92 (d, C-2′′), 110.70 (d, C-5′), 102.68
(d, Glc C-1), 84.84 (s, C-4), 84.31 (d, C-1), 82.55 (s, C-5), 79.93
(d, C-2), 76.22 (d, Glc C-5), 75.61 (d, Glc C-3), 73.11 (d, Glc
C-2), 70.13 (d, Glc C-4), 62.19 (t, Glc C-6), 57.24 (q, 1-OMe),
55.98 (q), 55.90 (2C, q) and 55.85 (q) (4 × Ar-OMe), 21.89 (t,
C-3); FABMS (pos.) m/z [M + Na]+ 571 (100), [M]+ 548 (4),
413 (24), 391 (16), 181 (25), 176 (41), 91 (55), 77 (55), 69 (75),
55 (100); HRFABMS (pos.) m/z [M + H]+ 549.2438 (calcd for
C
28H37O11 549.2335).
Part of fraction 5 (380 mg out of 960 mg) was separated on
a preparative HPLC column (C18, 32% MeOH in H2O) to give
two subfractions. The compounds in the first eluted subfrac-
tion, however, were decomposed during concentration. Upon
evaporation, the residue of the second subfraction was per-
acetylated with Ac2O-py. After general workup, the acetylated
products were separated on a Si gel column (230-400 mesh,
1% MeOH in CHCl3) to give curcapitoside peracetate (16 mg)1
and 1-O-methylcurculigine peracetate (6, 40 mg).3 Another
portion of fraction 5 (360 mg) was dissolved in MeOH and
O-methylated by reacting with freshly prepared ethereal
CH2N2 at 4 °C for 3 days. The residue (390 mg) obtained after
evaporating the organic solvents was separated on a Lobar
RP8 column (55% MeOH in H2O) to give four subfractions.
Subfractions 1 (140 mg) and 4 (30 mg) gave compound 2a (24
mg) and tetramethylnyasicoside (1a )6 (60 mg) (subfraction 1),
and 3a (8 mg) (subfraction 4) after separation by Si gel column
chromatography (230-400 mesh, 1% MeOH in CHCl3). Sub-
fraction 2 (48 mg), shown to be a mixture of tetramethyl-1-O-
methyl derivatives of curculigine and isocurculigine (7a , 8a )3
Tetr a -O-m eth ylcu r cu ligin e (4a ): amorphous powder; Rf
0.19 [MeOH-CHCl3 (1:9)]; [R]20D -21.7° [c 0.6, CHCl3-MeOH
(1:1)]; IR νmax 3400 (br s), 2950, 1665, 1590, 1510, 1420, 1280,
1160, 1080, 1020 cm-1; UV λmax (log ꢀ) 228 (4.40), 274 (4.12),
301 (3.88) nm; CD (c 1.81 × 10-5 M) (∆ꢀ) 326 (+0.19), 314 (0),
310 (+0.05), 302 (+0.06), 295 (-0.09), 286 (+0.15), 271 (-0.39),
266 (-0.34), 259 (-0.53), 246 (-0.17), 233 (-1.34), 209 (+0.44);
1H and 13C NMR, see Tables 2 and 3; FABMS (neg.) m/z (rel
int.) [M - H]- 551 (4), 537 (3), 377 (4), 303 (4), 287 (13), 229
(7), 197 (33), 179 (8), 153 (21), 139 (20), 107 (100).
Tetr a -O-m eth ylisocu r cu ligin e (5a ): amorphous powder;
Rf 0.19 [MeOH-CHCl3 (1:9)]; [R]20D -6.0° [c 0.5, CHCl3-MeOH
(1:1)]; UV λmax (log ꢀ) 228 (4.33), 274 (4.05), 300 (3.81) nm; IR
ν
max 3400 (br s), 2950, 1665, 1590, 1510, 1420, 1280, 1020 cm-1
;
CD (c 1.81 × 10-5 M) (∆ꢀ) 322 (+0.37), 313 (+0.14), 308
(+0.23), 302(+0.09), 294 (+0.29), 275 (-0.28), 267 (-0.29), 252
(+0.15), 248 (+0.08), 240 (+0.49), 229 (-0.07), 208 (-2.65);
1H and 13C NMR, see Tables 2 and 3; FABMS (neg.) m/z (rel
int.) [M - H]- 551 (4), 537 (3), 377 (6), 303 (4), 287 (18), 229
(12), 197 (36), 179 (9), 153 (12), 139 (26), 107 (100), 105 (15).
1
by H and 13C NMR spectral analysis, was further separated
by successive chromatography on a Lobar RP8 column (55%
MeOH in H2O) and a preparative HPLC column (C18, 40%
MeOH in H2O) to give 7a (16 mg) and 8a (9 mg). Fraction 6
(780 mg) was subjected to a Lobar RP8 column (30% MeOH in
H2O) to give 3′′-dehydroxynyasicoside2 (280 mg) and 1-O-
methylnyasicoside2 (10, 130 mg).
The MeOH-eluted fraction (980 mg) of the initial Amberlite
XAD-2 column was subjected to a Lobar RP8 column (54%
MeOH in H2O) to give compound 9 (98 mg).
1-O-Meth ylcu r cu ligin e Tetr a-O-m eth yl Eth er (7a): amor-
phous powder; Rf 0.33 [MeOH-CHCl3 (1:9)]; [R]23 -9.0° (c
D
1.0, MeOH); UV λmax (log ꢀ) 229 (4.19), 274 (3.90), 304 (sh, 3.68)
nm; IR νmax cm-1: 3400 (br s), 2950, 1665, 1590, 1520, 1420,
1280, 1035, 1020, 810, 770; CD (c 1.77 × 10-5 M) (∆ꢀ) 304
(+0.16), 298 (+0.23), 294 (+0.18), 286 (+0.47), 284 (+0.46),
278 (+0.52), 265 (+0.21), 253 (+0.34), 232 (-0.64), 212 (+0.75);
1H and 13C NMR, see Tables 2 and 3; FABMS (neg.) m/z (rel
int.) [M]- 566 (7), 552 (9), 377 (6), 321 (5), 301 (5), 287 (18),
285 (9), 229 (22), 219 (7), 210 (10), 197 (52), 195 (20), 179 (16),
171 (19), 155 (21), 153 (35), 139 (100), 105 (48), 89 (22).
Tetr a -O-m eth ylcu r ca p icyclosid e (2a ): amorphous pow-
der; mp 135-137 °C; UV λmax (log ꢀ) 230 (4.35), 276 (4.05),
308 (3.80) nm; [R]20 +58.3° [c 0.6, CHCl3-MeOH (1:1)]; IR
D
1-O-Meth ylisocu r cu ligin e Tetr a -O-m eth yl Eth er (8a ):
amorphous powder; Rf 0.33 [MeOH-CHCl3 (1:9)]; [R]23D +1.4°
(c 0.7, MeOH); IR νmax 3500 (br s), 2950, 1665 (CdO), 1590,
1520, 1410, 1280, 1120, 660 cm-1; UV λmax (log ꢀ) 229 (4.19),
274 (3.91), 307 (sh, 3.68) nm; CD (c 1.77 × 10-5 M) (∆ꢀ) 306
(-0.03), 294 (-0.29), 288 (-0.15), 277 (-0.20), 267 (-0.18),
262 (-0.21), 243 (0), 234 (+0.44), 225 (+0.28), 219 (0), [214
ν
max 3400 (br, OH), 2950, 1665 (CdO), 1590, 1520, 1420, 1280,
1020, 870, 800 cm-1; CD (c 1.87 × 10-5 M) (∆ꢀ) 311 (+1.30),
287 (0), 276 (-1.55), 250 (0), 235 (+2.93), 220 (+1.60), 212
(+2.43); H and 13C NMR, see Table 1; FABMS (pos.) m/z [M
1
+ H]+ 535 (4), 417 (5), 385 (8), 373 (12), 327 (12), 311 (12),
287 (10), 237 (27), 197 (40), 181 (42), 179 (33), 165 (49), 163
(25), 147 (43), 131 (26), 105 (32), 91 (100), 57 (51); HRFABMS
(pos.) m/z [M + H]+ 535.2208 (calcd for C27H35O11 535.2179).
P er a cetyla tion of 2a . Compound 2a (10 mg) was peracety-
lated with Ac2O-py at room temperature for overnight and
after general workup gave the peracetyl product 2b.
Tetr a -O-m eth ylcu r ca p icyclosid e Tr ia ceta te (2b): 1H
NMR data (CDCl3), see Table 1; HREIMS m/z [M]+ 660.2410
(calcd for C33H40O14 660.2418); EIMS m/z [M]+ 660 (4), 509
(3), 371 (24), 356 (6), 235 (8), 180 (16), 165 (100), 151 (10), 97
(10), 43 (12).
1
(+0.24), 208 (-0.42)]; H and 13C NMR, see Tables 2 and 3;
FABMS (neg.) m/z (rel int.) [M]- 566 (8), 551 (22), 377 (8), 287
(34), 269 (8), 229 (43), 197 (100), 179 (34), 139 (87), 87 (43).
Cu r ca p ita l (9): amorphous powder; Rf 0.28 [MeOH-H2O
(1:1), RP8]; IR νmax 3300 (br s), 1630, 1560, 1520, 1475, 1420,
1250, 1020, 870, 830, 790, 680 cm-1; UV λmax (log ꢀ) 221 (4.38),
1
250 (4.63), 276 (4.55), 309 (sh, 4.15), 376 (4.25) nm; H and
13C NMR, see Table 4; FABMS (neg.) m/z (rel int.) [M - H]-
309 (30), [M - 2H]- 308 (12), 279 (5), 203 (7), 171 (23), 137